Hikma Pharmaceuticals to participate in the world economic forum's industry strategy meeting

Amman, 28 June 2016 - Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces its participation in the World Economic Forum, Industry Strategy Meeting being held Tianjin, China from 26 to 28 June 2016.

Press Release Responsibility 28 June 2016

In 2016, Hikma became one of the World Economic Forum’s Health Industry Partners, with the objective of exploring new and improved ways of developing the standard of healthcare offered to patients globally. The upcoming strategy meeting in Tianjin is one of  the many initiatives established by the World Economic Forum to enable policy makers to focus on the industry challenges and to collaborate to enhance the quality of and access to healthcare.

Mazen Darwazeh, Hikma Executive Vice Chairman, President and CEO of MENA and Emerging Markets said:

“We are pleased to build on our partnership with the World Economic Forum reinforcing our shared vision of improving people’s lives around the globe. Through the forum’s platform, we are given the opportunity to converse with worldwide health leaders to develop new solutions that contribute to enhancing global healthcare. We share our rich experience as a multinational pharmaceutical company in understanding patients' needs in different regions."

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.